$TLPH

Talphera (TLPH) updated investors on its nafamostat mesylate clinical trial at the H.C. Wainwright conference. The NEPHRO study is 75% enrolled, with topline data expected in early 2025 and a potential U.S. launch in late 2025. The FDA reduced the study size to 70 patients, maintaining 90% statistical power. New guidelines recommend nafamostat, and the company sees a larger U.S. market opportunity. The stock has gained 56% over six months, with analysts setting price targets between $3 and $3.50

Talphera (Nasdaq: TLPH) reported Q2 2026 results and a corporate update on nafamostat. NEPHRO CRRT study enrollment is 75%, expected to finish by year-end. KDIGO 2026 draft guidelines cite nafamostat as an acceptable CRRT anticoagulant. Cash and investments were $17.1M at June 30, 2026; Q2 net loss was $4.3M.

TALPHERA, INC. (TLPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a posi

TALPHERA, INC. (TLPH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex_979677.htm EXHIBIT 10.1 ex_979677.htm Exhibit 10.1 AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN Originally Adopted by the Board of Directors: April 16, 2020 Originally Approved by the Stockholders: June 16, 2020 Amendment and Restatement Approved by the Board of D

Image source: The Motley Fool.Wednesday, November 12, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...

Talphera ( NASDAQ:TLPH ) , a specialty pharmaceutical company developing therapies for medically supervised hospital settings, reported its second quarter 2025 results on August 14, 2025. The company posted an EPS loss of $0.10 ( GAAP ) , which was better than the analyst consensus estimate of a ...

Talphera ( NASDAQ:TLPH ) reported second quarter 2025 results on August 14, 2025, highlighting accelerated clinical trial enrollment and a reduction in annual cash operating expense guidance to $16 million-$17 million for 2025.

Image source: The Motley Fool.Thursday, Aug. 14, 2025 at 4:30 p.m. ETChief Executive Officer - Vincent AngottiContinue reading ...

Talphera (TLPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).